Puma Biotechnology Inc. (PBYI)

6.76
0.03 0.44
NASDAQ : Health Technology
Prev Close 6.79
Open 6.79
Day Low/High 6.69 / 7.19
52 Wk Low/High 6.68 / 45.90
Volume 1.86M
Avg Volume 1.55M
Exchange NASDAQ
Shares Outstanding 38.90M
Market Cap 263.72M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of PBYI November 22nd Options Trading

First Week Of PBYI November 22nd Options Trading

Investors in Puma Biotechnology Inc saw new options become available this week, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new November 22nd contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 79,375...

First Week Of November 8th Options Trading For Puma Biotechnology (PBYI)

First Week Of November 8th Options Trading For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options begin trading this week, for the November 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new November 8th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology To Present At Cantor Global Healthcare Conference

Puma Biotechnology To Present At Cantor Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Announces U.S. FDA Acceptance Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

Puma Biotechnology Announces U.S. FDA Acceptance Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 4, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 48,750...

Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization For NERLYNX® (neratinib) For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer

Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization For NERLYNX® (neratinib) For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Agency of Medicines, Food and Medical Devices (ANMAT) in Argentina has granted approval of NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone...

Puma Biotechnology To Present At The H.C. Wainwright 21st Annual Global Investment Conference

Puma Biotechnology To Present At The H.C. Wainwright 21st Annual Global Investment Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Second Quarter 2019 Financial Results

Puma Biotechnology Reports Second Quarter 2019 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2019.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 52,501...

September 6th Options Now Available For Puma Biotechnology (PBYI)

September 6th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the September 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new September 6th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 9,125...

Puma Biotechnology To Host Conference Call To Discuss Second Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss Second Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

August 30th Options Now Available For Puma Biotechnology (PBYI)

August 30th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options begin trading today, for the August 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new August 30th contracts and identified one put and one call contract of particular interest.

Oversold Conditions For Puma Biotechnology (PBYI)

Oversold Conditions For Puma Biotechnology (PBYI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

August 23rd Options Now Available For Puma Biotechnology (PBYI)

August 23rd Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options begin trading today, for the August 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new August 23rd contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Presents Interim Results From The Biliary Tract Cohort Of Its Phase II SUMMIT Basket Trial Of Neratinib At The ESMO World Congress On Gastrointestinal Cancer 2019

Puma Biotechnology Presents Interim Results From The Biliary Tract Cohort Of Its Phase II SUMMIT Basket Trial Of Neratinib At The ESMO World Congress On Gastrointestinal Cancer 2019

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated interim results from the biliary cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, at the European...

First Week Of PBYI August 16th Options Trading

First Week Of PBYI August 16th Options Trading

Investors in Puma Biotechnology Inc saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Submits A Supplemental New Drug Application To U.S. FDA For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

Puma Biotechnology Submits A Supplemental New Drug Application To U.S. FDA For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has submitted a supplemental New Drug Application (sNDA) to the U.

Interesting PBYI Put And Call Options For August 9th

Interesting PBYI Put And Call Options For August 9th

Investors in Puma Biotechnology Inc saw new options begin trading today, for the August 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new August 9th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 3, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 82,063...

Puma Biotechnology Presents Results From Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer At The ASCO 2019 Annual Meeting

Puma Biotechnology Presents Results From Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer At The ASCO 2019 Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of...

CONTROL Trial Poster, June 2, 2019, ASCO 2019 Annual Meeting.

CONTROL Trial Poster, June 2, 2019, ASCO 2019 Annual Meeting.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago.

Puma Biotechnology To Present At Jefferies 2019 Global Healthcare Conference

Puma Biotechnology To Present At Jefferies 2019 Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Hold on Tight: Cramer's 'Mad Money' Recap (Monday 5/13/19)

Hold on Tight: Cramer's 'Mad Money' Recap (Monday 5/13/19)

Fasten your seatbelt, says Jim Cramer. Trade tensions are making for a wild ride on Wall Street, but stocks are almost in oversold territory.

TheStreet Quant Rating: D- (Sell)